Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.

@article{Ohtsu1999DefinitiveCF,
  title={Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.},
  author={Atsushi Ohtsu and Narikazu Boku and Kei Muro and Keisho Ch{\`i}n and Manabu Muto and Shigeaki Yoshida and Mitsuo Satake and Satoshi Ishikura and Takashi Ogino and Yoshinori Miyata and S Seki and Kazuhiro Kaneko and Akira Nakamura},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1999},
  volume={17 9},
  pages={
          2915-21
        }
}
  • A. Ohtsu, N. Boku, +10 authors A. Nakamura
  • Published 1999
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE To investigate the efficacy and feasibility of concurrent chemoradiotherapy for locally advanced carcinoma of the esophagus. PATIENTS AND METHODS Fifty-four patients with clinically T4 and/or M1 lymph node (LYM) squamous cell carcinoma of the esophagus were enrolled. Patients received protracted infusion of fluorouracil 400 mg/m(2)/24 hours on days 1 to 5 and 8 to 12, 2-hour infusion of cisplatin 40 mg/m(2) on days 1 and 8, and concurrent radiation therapy at a dose of 30 Gy in 15… Expand
Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus
TLDR
The results indicate that definitive chemoradiotherapy is potentially curative for locally advanced oesophageal carcinoma with malignant stricture. Expand
Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma
TLDR
Definitive chemoradiotherapy for ESCC is effective with substantial toxicities, and further investigation is warranted to minimize the normal tissue toxicities. Expand
Definitive Chemoradiotherapy with Capecitabine and Cisplatin in Patients with Esophageal Cancer: A Pilot Study
TLDR
Concurrent CRT with capecitabine and cisplatin was found to be well-tolerated and effective in patients with esophageal cancer. Expand
Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer.
  • S. Zenda, S. Hironaka, +6 authors T. Nishimura
  • Medicine
  • Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • 2008
TLDR
The pre-CRT Hb level may be an important determinant of outcome in patients with T4/M1 LYM squamous cell carcinoma of the esophagus treated with chemoradiotherapy (CRT). Expand
Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy
TLDR
This combined treatment with UFT and CDDP may be a promising nonsurgical management option for locally advanced esophageal cancer, and can achieve good palliative effects in patients with distant metastasis. Expand
Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula.
TLDR
This concurrent CT-RT protocol of protracted 5-fluorouracil infusion and cisplatin appears feasible and effective for T4 esophageal cancer with or without fistulas. Expand
Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.
  • S. Ishikura, K. Nihei, +6 authors S. Yoshida
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
Definitive CRT for SCC of the esophagus is effective with substantial toxicities, and additional investigation to minimize the normal tissue toxicities is warranted. Expand
Single-institute phase I/II trial of alternating chemoradiotherapy with 5-FU and nedaplatin for esophageal carcinoma.
TLDR
This intensive treatment for esophageal cancer was feasible and effective; however, moderate-to-severe toxicity occurred and this protocol warrants further clinical evaluation in a multi-institutional prospective study. Expand
Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease
TLDR
The overall survival for complete response patients with borderline-resectable disease was encouraging and further investigation to find a subgroup fit for esophagus-preserving treatment is warranted. Expand
Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer.
  • Sungbum Cho, H. Shim, +7 authors I. Chung
  • Medicine
  • Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • 2008
TLDR
Concurrent chemoradiotherapy with S-1 and cisplatin may be a promising nonsurgical treatment in advanced esophageal cancer. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 18 REFERENCES
Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus.
TLDR
Conurrent chemotherapy and radiotherapy was effective even for locally advanced esophageal carcinoma, but was associated with significant toxicity. Expand
Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma.
TLDR
An analysis of the results of 90 patients with esophageal cancer treated prospectively with combined chemotherapy and radiation without surgery and with a median follow-up of 45 months is presented, finding the pattern of failure may be altered from local to one dominated by distant metastases. Expand
Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study.
  • M. al-Sarraf, K. Martz, +7 authors B. Emami
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
TLDR
It is concluded that cisplatin and 5FU infusion given during and post-RT of 50 Gy is statistically superior to standard 64-Gy RT alone in patients with locally advanced esophageal cancer. Expand
Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report.
TLDR
Thirty-two percent of patients with residual tumor in the esophageal specimen are long-term survivors, which suggests a benefit from esophagectomy, with an approximate doubling of the 5-year survival rate. Expand
Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study.
TLDR
These studies demonstrate that the concurrent addition of modest dose cisplatin and infusional dose fluorouracil to radiation in the definitive, preoperative, and palliative settings contribute to high rates of durable dysphagia-free survival, with overall survival comparable to (and possibly better than) the chemoradiation arm of the recently reported Intergroup Study. Expand
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
BACKGROUND The efficacy of conventional treatment with surgery and radiation for cancer of the esophagus is limited. The median survival is less than 10 months, and less than 10 percent of patientsExpand
A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study.
TLDR
Postoperative adjuvant chemotherapy with cisplatin and vindesine has no additive effect on survival in patients with esophageal cancer compared with surgery alone, and there was no significant differences in survival even with lymph node stratification. Expand
Long‐Term Results of Subtotal Esophagectomy with Three‐Field Lymphadenectomy for Carcinoma of the Thoracic Esophagus
TLDR
Three-field lymphadenectomy, including especially the removal of bilateral recurrent nerve nodes in the cervical region, is essential for improving the survival of patients with carcinoma of the upper two thirds of the thoracic esophagus. Expand
Evaluation of the new (1987) TNM classification for thoracic esophageal tumors
TLDR
A total of 351 patients with thoracic esophageal carcinoma were prospectively classified according to the new TNM classification, and the following revisions are proposed: to group stage IIA and stage IIB together to form Stage II, to include cervical and coeliac lymph nodes among the regional lymph nodes, or to designate metastasis in non‐regional lymph nodes separately from metastasisIn viscera. Expand
Radical Lymph Node Dissection for Cancer of the Thoracic Esophagus
TLDR
The role of radical lymph node dissection in cancer of the thoracic esophagus was evaluated and it was concluded that survival rate was significantly better in patients with extensive three-field dissection. Expand
...
1
2
...